# Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

> **NCT02588456** · PHASE1 · TERMINATED · sponsor: **University of Pennsylvania** · enrollment: 5 (actual)

## Conditions studied

- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CART22 cells

## Key facts

- **NCT ID:** NCT02588456
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** This study was terminated due to lack of efficacy
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588456, "Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02588456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*